Hi Mozzark quick Q please . The AU results from trial are...

First 22 Last

Share
Profile

Follow
Timmmy

317 Posts.

52

01/02/22

11:02

Post #: 59268344
Share

Originally posted by Mozzarc: ↑

Short answer - Yes

Longer answer - Who knows but I guess there is a real chance of a deal in two distinct areas...MPS and OA. As Paul stated there is a chance that a company that we partner with could want a deal for both but I rate the chance of two separate deals slightly higher. Why? Because MPS is so specific...is a different market, has different dynamics under the Orphan drug designation and thus path to eventual commercialisation.

Most likely PAR will partner up separately in the MPS space to fund a required P3.

There are multiples ways this could fly...we don't know the timing but in theory a deal in either or both indications could take place this year as Paul mentioned in the recent AGM. No doubt cash burn will be a factor but PAR are also adequately mindful of what they are worth. The one year blinded pricing research they conducted last year no doubt adds a lot of insight to what they already suspected in terms of what potentially our RRP might be and thus valuation.

Hard to imagine how a meaningful deal couldn't eventuate with the excellent data we have garnered so far, the unheard of safety profile and the magic of disease regression (at least in some cases) which we have all read about and also await from the company. The all important patient testimonials and PGIC all add weight to our drug's performance.

For a deal to happen we don't necessarily have to wait for 008 final read out, the big boys and girls would already know what's coming, the efficacy of iPPS in the synovium and the serum, its incredible impact on inflammatory cytokines, the binding nature this molecule has when tackling the various osteo pathophysiologies...

Par-Peeps, there is no other OA drug that work in multiple ways...that assists in the higher weighted production of the vital HA...that helps to fortify the extra cellular scaffolding and that simply reduces pain without joint destruction. What drug do you know of reduces the cytokine storm, has efficacies in terms of cellular membranes surrounding the synovium to allow for more nutrient pass through and stimulate many reactions and biological processes that combine to tackle OA at multiple levels?

Let them do their DD and come back to us with a deal just too awesome to refuse.

(Big Brother/Sis Future Bio Partner extraordinaire, if you are reading this, do also cover appropriate Due Diligence on NGF and our molecule's amazing down regulation of this too...and don't forget the amazing reductions being experienced through the BBB that the MPS society have noted along with the work being done at Icahn Medical, Mt Sanai).

So yes, we burn cash...but we still have some time... something will strike...when it does, these short term problems will be long behind us.

DYOR

Expand

Hi Mozzark quick Q please . The AU results from trial are released in Q3 22 and the US trials finnish enrolment Q122 but when do you envisage the first results from the US also how long after this release would it take for the product be available for sale provided we have partners.all in your opinion
Thank you so much

PAR Price at posting: $1.49 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ALR

Altair Minerals hits high-grade copper and gold at Wee MacGregor, QLD

SNG

Siren Gold boosts antimony resource by 66% to 14.5Kt at Auld Creek, NZ

WMG

Western Mines identifies 2 high-grade zones at Mulga Tank in WA

PTR

Petratherm adds $1.6 to the piggybank ahead of SA titanium drilling program

WR1

Winsome scoping study proposes low-cost operation for Adina lithium project

There are more pages in this discussion • 7 more messages in this thread...

First 22 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 26.0¢		Change 0.010(4.00%)		Mkt cap ! $91.06M

Open	High	Low	Value	Volume
25.0¢	26.0¢	25.0¢	$36.40K	143.5K

Buyers (Bids)

No.	Vol.	Price($)
1	40816	24.5¢

Sellers (Offers)

Price($)	Vol.	No.
26.0¢	44646	4

View Market Depth

No.	Vol.	Price($)
1	40816	0.245
3	50491	0.240
6	123811	0.235
8	113649	0.230
8	120467	0.225

Price($)	Vol.	No.
0.260	44646	4
0.265	96349	5
0.270	40288	5
0.275	13636	2
0.280	111247	8

Last trade - 16.10pm 17/09/2024 (20 minute delay)

PAR (ASX) Chart

Hi Mozzark quick Q please . The AU results from trial are...

Altair Minerals hits high-grade copper and gold at Wee MacGregor, QLD

Siren Gold boosts antimony resource by 66% to 14.5Kt at Auld Creek, NZ

Western Mines identifies 2 high-grade zones at Mulga Tank in WA

Petratherm adds $1.6 to the piggybank ahead of SA titanium drilling program

Winsome scoping study proposes low-cost operation for Adina lithium project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Hi Mozzark quick Q please . The AU results from trial are...

Top Stories

Altair Minerals hits high-grade copper and gold at Wee MacGregor, QLD

Siren Gold boosts antimony resource by 66% to 14.5Kt at Auld Creek, NZ

Western Mines identifies 2 high-grade zones at Mulga Tank in WA

Petratherm adds $1.6 to the piggybank ahead of SA titanium drilling program

Winsome scoping study proposes low-cost operation for Adina lithium project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News